colitis semaglutide Patients with stable inflammatory bowel disease (IBD) and comorbid obesity and/or diabetes who started GLP-1 receptor agonists (semaglutide or tirzepatide) alongside ongoing treatment did not have a lower risk for the relapse GLP-1s and Ulcerative Colitis: Safety

doi: 10.3389/fpsyt.2022.1002828 Received 25 July 2022 Accepted 10 October 2022 Published 15 November 2022 Volume 13 - 2022 Edited by Bharathi Gadad, Texas Tech University Health Sciences Center El Paso, United States Reviewed by Federica Ferrari, University of Pavia, Italy

A.YeD.PedramA.SaidH

Dengan pemakaian nature e white secara rutin, kulitmu akan tampak lebih halus dan pastinya jadi lebih percaya diri

Potential Side effects : Dry mouth, insomnia, dizziness, irritability, nausea, constipation, elevated heart rate, elevated blood pressure, restlessness, and anxiety

Review current FDA warnings and understand this peptide is NOT approved or regulated as a treatment